FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA, Others Launch Global Substances System

FDA says it is working with the National Institutes of Health and the European Medicines Agency on a global substance registration system.

latest-news-card-1
Human Drugs

Califf Touts Progress in Drug Compounding Oversight

FDA commissioner Robert Califf says FDA and its state and federal partners have made great progress in oversight of drug compounding, but there are st...

latest-news-card-1
Human Drugs

Updated Meeting Definitions

FDA posts updated definitions of face-to-face meeting formats to the PDUFA 7 and BsUFA 3 Web pages.

latest-news-card-1
Federal Register

Guidance on Oncology Cross-Labeling

Federal Register notice: FDA makes available a final guidance entitled Cross Labeling Oncology Drugs in Combination Regimens.

latest-news-card-1
Federal Register

Comments Sought on Premarket Safety Workshop

Federal Register notice: FDA requests comments on the topics discussed at its 9/14 public workshop entitled Advancing Premarket Safety Analytics Works...

latest-news-card-1
Federal Register

Guidance on Pharmaceutical Carcinogenicity Testing

Federal Register notice: FDA makes available a final guidance entitled S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals.

latest-news-card-1
Human Drugs

Oncology Drug Cross Labeling Guidance

FDA publishes a guidance on cross-labeling of oncology drugs used in combination regimens.

latest-news-card-1
Medical Devices

Teleflex Filter Recall is Class 1

FDA says the Teleflex recall of 60,000 Iso-Gard Filter S units is Class 1.

latest-news-card-1
Human Drugs

Temporary Clozapine REMS Enforcement Discretion

FDA announces new enforcement discretion and reiterates previous enforcement discretion relating to issues with the clozapine REMS program.

latest-news-card-1
Federal Register

Guide on Expanded Access for Investigational Drugs

Federal Register notice: FDA makes available a revised draft guidance entitled Expanded Access to Investigational Drugs for Treatment Use: Questions a...